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Listeria innocua DNA binding protein from starved cells (LiDps) belongs to the ferritin family and provides a promising self-assembling
spherical 12-mer protein scaffold for the generation of functional nanomaterials. We report the creation of aGaussia princeps luciferase (Gluc)-
LiDps fusion protein, with chemical conjugation of Zinc (II)-protoporphyrin IX (ZnPP) to lysine residues on the fusion protein (giving Gluc-
LiDps-ZnPP). The Gluc-LiDps-ZnPP conjugate is shown to generate reactive oxygen species (ROS) via Bioluminescence Resonance Energy
Transfer (BRET) between the Gluc (470-490 nm) and ZnPP. In vitro, Gluc-LiDps-ZnPP is efficiently taken up by tumorigenic cells (SKBR3
and MDA-MB-231 breast cancer cells). In the presence of coelenterazine, this construct inhibits the proliferation of SKBR3 due to elevated
ROS levels. Following exposure to Gluc-LiDps-ZnPP, migration of surviving SKBR3 cells is significantly suppressed. These results
demonstrate the potential of the Gluc-LiDps-ZnPP conjugate as a platform for future development of an anticancer photodynamic therapy agent.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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2Photodynamic therapy (PDT) is an emerging therapeutic
modality for non-invasive and tissue selective treatment of
cancer and other diseases.1 Success of the treatment relies on
excitation of a non-toxic photosensitizer in the presence of
oxygen to generate singlet oxygen (via a type II photochemical
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0/).(via a type I photochemical reaction). ROS are strong oxidizing
agents which attack DNA, proteins and lipids causing irrevers-
ible damage to cells.3 Several PDT agents have already been
used for clinical treatment of age-related macular degeneration4
and proposed for the treatment of various carcinomas.5–7
Because the photosensitizers require light for activation, most
of the clinical studies against cancer have focused on treating
tumors that are on or just below the surface of the skin or in the
exterior lining of internal organs and cavities, given the light
penetration at the wavelengths required is normally less than
1 cm due to absorption and scattering caused by the tissue.8
Strategies for overcoming this have recently been reviewed.9–11
Selective targeting of PDT agents to diseased tissues is required
to reduce the collateral damage to healthy cells,12 however
achieving specificity and selectivity in PDT, beyond controlling
the area illuminated, remains challenging.s article under the CC BY license (http://creativecommons.org/licenses/by/4.
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option for avoiding the need for an external light source and allowing
localized treatment of tumors deeper in a patient's body.13 The
efficiency of a BRET pair relies on overlap of the bioluminescent
emission generated by luciferase enzymes or photoproteins and the
absorption of the photosensitizer which must be located within 10-
100 nm of each other. Within the luciferase family, Gaussia
luciferase (Gluc) from the marine copepod G. princeps offers
several advantages over other luciferases including its low
molecular weight (19.9 kDa),14 and bright peak bioluminescence
at 480 nm.15 Also, unlike other luciferases there are, no
requirement for ATP or any other cofactors,16 only the
coelenterazine (luciferin) substrate to generate light. It has been
demonstrated that luciferases and luciferins are non-toxic to many
different cell types.17,18
Among various photosensitizers, zinc (II) protoporphyrin IX
(ZnPP) has attracted significant interest as it has shown the ability to
generate singlet oxygen upon illumination with visible light with a
quantum yield of 0.91.19,20 A potential scaffold for the donor-
acceptor BRET pair could be provided by Listeria innocua DNA
binding protein from starved cells (LiDps). This protein from the
ferritin family, a so-called ‘mini-ferritin’ is composed of twelve
subunits (each 19 kDa) that assemble into a spherical cage with an
external diameter 9 nm and hollow central cavity with a diameter of
4.5 nm,21,22 which in addition, could be used for delivery of
therapeutic agents. This scaffold has a number of advantages: it is
readily expressed in E. coli and has no cysteine residues. The self-
assembly of the scaffold is pH and [urea] sensitive with the capsule
disassociating at pH 2.0 allowing differently functionalized subunits
to be combined to give capsules with a variety of stoichiometries,-
23,24 it allows proteins to be fused to both its N- andC-terminiwhich
are on the exterior of the protein capsule without affecting capsule
assembly,25 fusion of small proteins such asGaussia luciferase to
the Dps capsule prevents them from being removed by glomerular
filtration in the kidneys significantly extending their circulation
time as the capsule is above the ~70 kDa glomerular filtration
threshold cut-off,26 this protein scaffold unlike many polymeric or
inorganic nanoparticle based systems is also fully biodegradable
removing any concerns of persistence within the body. Dps is an
iron (II) scavenging protein that possesses ferroxidase activity. It is
thought that their natural role is to prevent DNA from Fenton
mediated oxidative stress in L. innocua as it catalyzes iron(II) to
iron(III) oxidation in the presence of hydrogen peroxide reducing
the production of hydroxyl radicals that can damage DNA.27 The
ferroxidase activity is lost in the absence of iron or in the H31G-
H43G and H31G-H43G-D58A mutants.28
To date, a very small number of other BRET-based PDT agents
have been reported: Rose Bengal sensitiser conjugated to Renilla
luciferase,13 Renilla luciferase-immobilized quantum dots-655
(QD-RLuc8) in combinationwithmeta-tetra(hydroxyphenyl)chlorin
(m-THPC) (temoporfin/Foscan)-loaded micelles29,30 and Renilla
luciferase (Rluc8) conjugated carboxylated 655-nm quantum dots
and chlorin e6.31 In an alternative approach, the luciferase gene can
be transfected into the cells and the sensitizer added separately:
A firefly luciferase-based system for the excitation of Rose Bengal
in NIH 3T3 murine fibroblasts was described by Theodossiou
in 2003,32 although these results have been contested.33,34 This
approach is limited by the need to deliver the gene for the luciferaseselectively to the tumor cells only, which is currently not possible in
the clinic, however application of chemiluminescence and biolumi-
nescence in PDT continues to attract considerable attention.35
Here we report the development of a new biocompatible
multifunctional nanoplatform with potential applications as a
‘self-illuminating’ PDT agent. Gluc has been genetically fused to
the N-terminal of LiDps subunits and the lysine residues on the
resulting fusion protein surface have been conjugated with ZnPP.
The Gluc-LiDps-ZnPP conjugate operates via BRET where the
coelenterazine is excited by Gluc and transfers its energy to
the photosensitizer (ZnPP) resulting in the production of ROS.
In vitro, Gluc-LiDps-ZnPP is efficiently sequestered by tumor
cells and, in the presence of the coelenterazine, inhibits the
proliferation of breast cancer cells SKBR3 due to ROS generation
in a self-contained photodynamic therapy system. Remarkably,
following exposure to Gluc-LiDps-ZnPP, the cell migration of
surviving cells is also significantly suppressed. These results
demonstrate the realistic potential of the Gluc-LiDps-ZnPP
nanoconstruct as a starting point for the development of an
anticancer PDT agent.Methods
Cloning of Gluc-LiDps
Both LiDps and Gluc genes were constructed in pJexpress
vectors with the LiDps gene being a gift from Dr. Phil Hill,
University of Nottingham and Gluc being a synthetic gene
(DNA2.0) having been codon optimized for E. coli protein
expression. An E. coli vector was constructed by sub-cloning the
Gluc gene from plasmid pJexpress414 into pJexpress411 which
contained the LiDps gene. The Gluc gene was fused to the N-
terminal of LiDps via a DNA sequence encoding a flexible
pentaglycine linker and thrombin cleavage site peptide
(TGGGGGGLVPRGS). To assist purification, DNA encoding
a hexa-His-tag was placed at the N-terminal of the Gluc protein.
The complete amino acid sequence of the Gluc-LiDps construct is
given in the supplementary information.
Expression and purification of Gluc-LiDps
Gluc-LiDps expression was induced by IPTG (1 mM) (Fisher
Scientific) overnight (~16 h) in cultures of E. coli BL21 (DE3)
carrying the pJexpress411:Gluc-LiDps plasmid and grown in
Luria Bertani (LB) medium supplemented with kanamycin
(50 μg /mL) (Apollo Scientific) at 30 °C. Cells were harvested
by centrifugation at 2500 ×g for 25 minat 4 °C, resuspended in
40 mL buffer (20 mM Tris pH 8.3 (Fisher Scientific), 10 mM
imidazole (Sigma Aldrich)) with 1 mM phenyl methyl sulfoxide
(PMSF) (Sigma Aldrich) and lysed by sonication. After
centrifugation at 22,000 ×g for 25 min at 4 °C, the resulting
pellet was resuspended in the IMAC binding buffer (20 mM Tris
pH 8.3, 10 mM imidazole, 4 M urea (Fisher Scientific)) and
centrifuged again at 35,000 ×g. The protein solution was loaded
on a 5 mL nickel column (GEHealthcare) andwashed 3×with the
column volume of binding buffer. Gluc-LiDps was then eluted
using a linear gradient of increasing imidazole concentration up to
500 mM. Following purification, the Gluc-LiDps was refolded
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20 mMNa2HPO4 pH 8.3 (Fisher Scientific)) using 6-8 KMWCO
dialysis tubing (SpectrumLaboratories). The Gluc-LiDps fractions
were identified using SDS-gel electrophoresis. The fractions
containingGluc-LiDps were pooled and loaded on a size exclusion
column (Superdex 75 10/300 GL). Eluted fractions were analyzed
using SDS PAGE and the Gluc-LiDps concentration was
determined by absorbance measurements (extinction coefficient =
24,575 M cm−1) using a NANODropA-1000 spectrophotometer.
The yield of protein refolding was 5 mg per 1 L of culture.
Spectrophotometric measurements
Serial dilutions of Gluc-LiDps and Gluc-LiDps-ZnPP with
final concentrations of 0.5, 1, 5, and 10 μg/mL were prepared
using phosphate buffer (20 mMNa2HPO4, pH 8.3). The samples
were mixed with 2, 4, or 6 μg/mL of coelenterazine in the
presence and absence of 0.1% (w/v) SDS in a white 96 well
opaque plate (PerkinElmer) and were analyzed using a
microplate reader (En Vision 2104 Multilabel Reader). Coelen-
terazine (Nanolight Technologies, Arizona USA) was dissolved
in methanol (0.5 mg per 20 μL) and added to 118 μL of
phosphate buffer. Coelenterazine stock solutions (10 mM) were
stored at −80 °C.
Chemical modification of Gluc-LiDps subunits with ZnPP
A general procedure36 was followed. Briefly, the ZnPP-NHS
ester was prepared by mixing 50 μL of ZnPP (40 mM) in
DMSO solution with 8 μL of 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDC) (500 mM) and then
8 μL of N-hydroxysuccinimide (NHS) (500 mM) being added
(ZnPP:EDC:NHS = 1:2:2). The resulting solution was stirred for
15 min and centrifuged at 5000 ×g for 5 min to remove the
soluble isourea by-product and excess reagents. The purified
Gluc-LiDps fusion protein 800 μL (0.7575 mM) (contains 30
lysine residues + N-terminal amine per subunit) was incubated
with 200 μL activated ZnPP-NHS ester (30.3 mM) at a molar
ratio of 1:10 of Gluc-LiDps to ZnPP-NHS. After 24 h at room
temperature, the unreacted materials were removed by dialysis
(2 × 2 L) of phosphate buffer (20 mM Na2HPO4, pH 8.3) using
6-8 K MWCO dialysis tubing (Spectrum Laboratories). Samples
were then filtered through (C18) Zip-Tips spraying from 80:20
MeCN:H2O + 0.1% TFA (v/v) and analyzed using an electro-
spray ionization mass spectrometer (SYNAPT HDMS).
Circular dichroism study
The circular dichroism studies were performed at room
temperature (25 °C) on Gaussia (5 μM), DPS (4 μM) and
Gaussia-DPS (1 μM). The 20 mM phosphate buffer was
used (pH = 8.3). Measurements were performed on Applied
Photophysics Chirascan-Plus fitted with a Quantum Northwest
temperature controller (JASCO UK).
Cell culture study
Immortal non-tumorigenic and carcinoma cells were selected
for this study: SKBR3 (ATCC® HTB-30™) and MDA-MB-231
(ATCC® HTB-26™) breast cancer epithelial cells, with MRC5
(ATCC® CCL-171™) fetal lung fibroblast cells (all from theAmerican Type Tissue Collection (ATCC)) as the non-tumor-
ogenisis control. These were cultured under optimum conditions
in RPMI nutrient medium (Sigma-Aldrich) supplemented with
10% fetal bovine serum (FBS) (SigmaAldrich), and subcultivated
twice weekly to maintain logarithmic growth. MRC5 cells were
cultured usingMinimum Essential Medium (MEM) supplemented
with 10% (v/v) of FBS, L-glutamine (200 mM), non-essential
amino acid (10×), HEPES (1 M, pH 7.0-7.6), sodium bicarbonate
(7.5%), and penicillin–streptomycin solutions (10,000 Upenicillin
and 10 mg streptomycin/mL; used at recommended quantity of
10 mL/L) (Sigma Aldrich). For the MTT assay, cells were seeded
into 96-well plates at a density of approximately 3 × 103 cells/well
and allowed to adhere to the plates by incubating at 37 °C for 24 h
in a 5% CO2 atmosphere. The cells were treated with Gluc-LiDps-
ZnPP at final concentrations between 0.1 μg/mL and 100 μg/mL
for 1, 2, 3, 4, 5, or 24 h at 37 °C to allow the uptake of the agent.
The medium with excess Gluc-LiDps-ZnPP agent was aspirated
and washed twice with 200 μL of PBS. A 200 μL of fresh medium
with coelenterazine (5 μg/mL) was added and the cells were
further incubated at 37 °C for 72 h in a 5%CO2 atmosphere. MTT
(SigmaAldrich), 50 μL (2 mg/mL) was added to each well to give
a total volume of 250 μL and incubated for 3 h at 37 °C in a 5%
CO2 atmosphere. The medium was aspirated. DMSO was used to
dissolve the formazan crystals. For studies in 96 well plates,
formazan crystals were solubilized with 150 μL of DMSO per
well. The absorbance was measured at 550 nm using an En Vision
2104 Multilabel microplate reader (PerkinElmer).
To probe the cellular uptake, cells were seeded at 3.5 × 105
cells/well in a total medium volume of 2 mL in a 6-well plate
for 24 h before treatment with 2 mL of Gluc-LiDps-ZnPP
(14.8 μg/mL) for 1, 3, and 6 h. The cells were then washed twice
with PBS (2 mL), trypsinized (500 μL, trypsin–EDTA 0.25%
(w/v) solution, Sigma Aldrich), pooled together with 1 mL of
fresh RPMI nutrient medium and centrifuged at 1200 ×g for
5 min (Beckman Coulter Allegro). The cell pellet was washed
twice with PBS (1 mL), centrifuged and resuspend in 0.5 mL of
PBS. Samples were analyzed using an Astrios EQ flow
cytometer with excitation at λ = 425 nm and the data were
analyzed using Kaluza Flow Cytometry Analysis Software
(Beckman Coulter).
The ROS-Glo™ H2O2 kit (Promega) was used to determine
the intracellular ROS levels. Cells were seeded at a density of
5 × 104 cells/well in white 96-well plates and treated after 24 h
with 14.8 μg/mL of Gluc-LiDps-ZnPP in the presence of 5 μg/
mL coelenterazine. The H2O2 substrate (20 μL) was mixed with
80 μL of treated cell culture and incubated for 6 h. The detection
solution (luciferin detection reagent, D-cysteine and Signal
Enhancer Solution (Promega); 100 μL) was added and the cells
were incubated for 20 min at room temperature before
luminescence detection at (λ = 520 nm) using a microplate
reader (En Vision 2104 Multilabel microplate reader
(PerkinElmer).
For the wound healing (migration) assay, SKBR3 cells were
seeded in a 35 mm μ-Dish containing two medium chambers
separated by a membrane (ibidi GmbH, Munich, Germany) at a
density of 35 × 103 cells/well and incubated for 24 h. After the
membrane was removed, the dish surface was filled with 2 mL of
the medium containing 7.4 μg/mL of Gluc-LiDps-ZnPP. The
Figure 1. (A) Schematic representation of a mechanism of the structure of Gluc-LiDps-ZnPP and generation of ROS. (B) Photograph of a native agarose gel
under UV illumination (λex = 300-400 nm) (left) and stained with Coomassie brilliant blue R-250. Human apo-ferritin (HuAFn) (561 kDa), and LiDps
(257 kDa) proteins were used as molecular weight markers after their mass was determined by ESI-MS. Molecular weight of Gluc-LiDps is estimated to be
459 kDa and Gluc-LiDps-ZnPP to be ~515 kDa.
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migration was followed by tracking the images every 8 h using a
Nikon ECLIPSE TS 100 microscope. The images were analyzed
using ImageJ (Fiji) software.
Confocal microscopy studies
Cells were seeded at a density of 1 × 104 cells/well in an 8
well μ-slide confocal chamber (ibidi GmbH, Munich, Germany)
and incubated overnight. Following 1, 3 and 6 h treatment with
Gluc-LiDps-ZnPP, the cells were washed 3 times with 200 μL
of PBS, fixed using 200 μL of 4% (v/v) formaldehyde for 20 min
and washed with PBS (3 × 2 μL). The fixed cells were stained
with DRAQ5™ DNA stains before washing with 200 μL PBS
(3 × 2 μL). Imaging was performed on a confocal microscope(LEICA DMI 4000 B) set at λex = 425 nm and λem = 593 nm.
The images were analyzed using ImageJ (Fiji) software.
Statistical analysis
The data were analyzed using one-way, two-way analyses of
variance (ANOVAs), and t test as appropriate usingGraphPad Prism
ver. 6. The statistical differences were assessed using the ANOVA
method and a significant effect was identified if P b 0.05.
Results
The construction of Gluc-LiDps-ZnPP
The Gluc-LiDps-ZnPP conjugate was constructed using the
natural LiDps gene and a synthetic Gluc gene (with hexa
Figure 2. The normalized luminescence intensity measured at λ = 470 nm
for Gluc-LiDps and for Gluc with and without SDS (normalized to intensity
at time 0). Error bars represent average value over three independent repeats.
Left inset shows a photograph of blue light emitted by the Gluc-LiDps
construct. Right inset shows a spectral overlap between the bioluminescence
of Gluc and absorption of ZnPP.
Figure 3. Time dependent growth inhibitory effect of Gluc-LiDps-ZnPP with
coelenterazine on SKBR3, MDA-MB-231 and MRC5 cells represented at
normalized absorbance at 550 nm (normalized to control). Values are
mean ± SD of three independent experiments. Statistically significant
differences are labeled as ***P b 0.001 and **P b 0.01.
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(TGGGGGGLVPRGS) between the proteins). The presence of
Gluc-LiDps gene was confirmed by DNA sequencing (Figure
SI2). It was found that ~7 lysine residues in each Gluc-LiDps
fusion protein could be chemically labeled with ZnPP molecules
(Figure 1 and SI1). The fusion protein was expressed in E. coli
and purified using nickel (II) IMAC and gel filtration. The SDS
PAGE gel revealed a band at the expected molecular weight for
the Gluc-LiDps construct (theoretical mass = 38.242 kDa), which
was also confirmed by nano-electrospray (nESI) mass spectrosco-
py (measured mass = 38.241 kDa) (Figure SI3). These results, in
combination with native PAGE and morphological characteriza-
tion using TEM (Figures 1,B and SI4), confirmed that Gluc-LiDps
was isolated in high purity and forms a nanocage of 12 subunits
with the diameter expected.
Bioluminescence of the Gluc-LiDps and BRET of the
Gluc-LiDps-ZnPP nanoconstructs
Gluc-LiDps activity was tested by adding the coelenterazine
substrate (50 μL at final concentration 4 μg/mL) to the purified
protein (100 μL at final concentration 5 μg/mL). Upon addition,
blue luminescence light was immediately observed. We found that
the light intensity in the presence of Gluc on its own, decayed up to
2× faster compared to that in the presence of the Gluc-LiDps fusion
protein (see Figure SI5), and this was independent of coelentrazine
concentration (2, 4, and 6 μg/mL). The causes of prolonged
lifetime, were probed by addition of 10 μL of sodium dodecyl
sulfate to the reaction mixture containing 5 μg/mL of Gluc and
4 μg/mL of coelenterazine. The SDS is commonly used to
disassemble multi-subunit proteins,37,38 thus reducing steric
hindrance for substrates. Hence we used this approach to confirmthat activity observed is related to Gluc-LiDps construct and
provides additional evidence for its successful formation. We
found that after addition of SDS (0.1%w/v) to the reactionmixture
(100 μL of final concentration of 5 μg/mL Gluc-LiDps or Gluc
both with 4 μg/mL of 50 μL of final concentration of coelenter-
azine), the fluorescence decay of Gluc-LiDps became comparable
to that of Gluc alone (Figure 2).
To achieve an active BRET pair that generates ROS, Gluc-LiDps
lysine residues were conjugated with ZnPP pre-activated using
EDC/NHS and dialyzed to remove unconjugated ZnPP and products
of the coupling reaction. The conjugation efficiency was examined
by SDS PAGE and nESI mass spectrometry. We achieved the
optimal level of conjugation with a molar ratio of 1:10 for Gluc-
LiDps:ZnPP (Figure SI6). The molecular weight of subunits
was estimated to be 38,241.7 Da/subunit and increased to
42,938 Da/subunit following ZnPP conjugation. From the combi-
nation of nESI-MS results and SDS PAGE, we have estimated that
~7ZnPPmolecules per subunitwere attached to theGluc-LiDps.We
note, that the Gluc-LiDps protein precipitated when higher levels of
ZnPP (at ratios greater than 1:10 of Gluc-LiDps:ZnPP) were used in
the labelling process, probably due to the reduction in polar/ionized
amino acids on its surface. Native PAGE studies confirm that the
chemicallymodified proteins formed a protein cage and indicate that
Gluc-LiDps-ZnPP migrates faster through the gel compared to
Gluc-LiDps, in accord with a change of the net charge (pI) arising
from neutralization of some of the positively charged lysine residues
after conjugation of ZnPP (Figure 1, B).
Inset in Figure 2 illustrates the overlap of luminescence of Gluc
and absorption of ZnPP, which is expected to lead to BRET in
Gluc-LiDps-ZnPP.Here the bioluminescence energy of the excited
coelenterazine generated by Gluc (emission λGluc =470 nm) is
efficiently absorbed by ZnPP (absorption λZnPP =425 nm).
Figure 4. Confocal images of MRC5, MDA-MB-231 and SKBR3 cells demonstrating uptake of Gluc-LiDps-ZnPP after 6 h incubation; blue fluorescence is
indicative of the Gluc-LiDps-ZnPP, red fluorescence is indicative of DRAQ5 DNA stain; the overlay of Gluc-LiDps-ZnPP and DRAQ5 in the second column is
shown that the Gluc-LiDps-ZnPP is primarily localized in the cytoplasm. Scale bar in all images in 20 μm.
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To assess the potential of Gluc-LiDps-ZnPP to act as a PDT
agent, we selected two breast cancer cell lines: the triple negative
MDA-MB-231 cell line, and the HER2 overexpressing SKBR3
cell line. In addition, the MRC5 fibroblast cell line from fetal lung
tissue was included as a non-tumorigenic control to enable
differentiation between agents that are general toxins and those
which are truly cancer cell line specific. The fibroblast cells are notimmortal, they can only divide a set number of times before they
senesce and eventually die, however their DNA integrity is
maintained providing protection from cancer formation, hence
they provide direct comparison for toxicity screens that depend
upon proliferation of cells (such as the MTT assay).
The inhibitory growth effects of the Gluc-LiDps-ZnPP in the
presence of the coelenterazine were probed using a cell viability
(MTT) assay. In order to discriminate between the effects of
individual components and that of the nanocage conjugate, cellswere
Figure 5. ROS levels generated in SKBR3 and MDA-MB-231 cells treated
with Gluc-LiDps-ZnPP and coelenterazine compared to untreated (control)
cells. Values are mean ± SD of three independent experiments. Statistically
significant differences are labeled as ***P b 0.001.
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with and without the coelenterazine for 72 h. For coelenterazine
alone, no toxic effects were observed following exposure of
up to 5 μg/mL of the coelenterazine to the cells, thus this
concentration was chosen for further studies (Figure SI7). The
maximum exposure concentrations of individual components
were selected to correspond to their equivalent concentrations in
100 μg/mL of Gluc-LiDps-ZnPP.
We found that only exposure of cells to Gluc-LiDps-ZnPP at
concentrations N14.8 μg/mL in the presence of coelenterazine
(5 μg/mL) led to significant growth inhibition of SKBR3 cells.
In contrast, the viability of MDA-MB-231 and MRC5 cells
was not affected up to 100 μg/mL (Figure SI8). The time
dependent growth inhibition study supported the results of
the MTT assays. After 72 h incubation, a clear time-dependent
response was observed only in SKBR3 cells and not the other
two cell lines (Figure 3).
Flow cytometry studies were performed following treatment
of the cells with Gluc-LiDps-ZnPP at a concentration of
29.6 μg/mL and demonstrated that most of the Gluc-LiDps-
ZnPP was taken up within 3 h of exposure. The cellular
uptake by SKBR3 is 2× higher when compared to that with
MDA-MB-231 cells (Figure SI9–10 and Table 1 & 2 in SI).
Confocal microscopy revealed no detectable emission in the
non-tumorigenic MRC5 cells and preferential location of
the Gluc-LiDps-ZnPP agent in the cytoplasm of SKBR3 and
MDA-MB-231 tumorigenic cells with significantly greater
uptake of the Gluc-LiDps-ZnPP agent is observed in the former.
(Figures 4 and SI11).
In order to determine the increase of intracellular ROS
caused by the Gluc-LiDps-ZnPP plus coelenterazine, a ROS
assay was used. The results show that ROS generation was two-
fold higher in SKBR3 cells treated with Gluc-LiDps-ZnPP in thepresence of coelenterazine compared to the SKBR3 cells treated
separately with each individual compound (Gluc-LiDps-ZnPP,
Gluc-LiDps, and ZnPP). The ROS in the MDA-MB-231 cell
line was half that observed in the SKBR3 cells (Figure 5) which
correlates with the different levels of uptake of the PDT agent in
these two cell lines.
The effect of Gluc-LiDps-ZnPP plus coelenterazine on SKBR3
cell migration was identified by determining its ability to suppress
a ‘scratch’ wound in a layer of cells over time. SKBR3 cells
(35 × 103 cells/well) were treatedwith 2 mLof final concentration
of 7.4 μg/mL of Gluc-LiDps-ZnPP for 5 h before adding of 2 mL
of final concentration of 5 μg/mL of coelenterazine. The wound
was created by a membrane separating the two cell chambers and
cell migration was tracked every 8 h. Following 40 h observation,
it was evident that exposure to the agent has significantly
reduced SKBR3 cell migration compared to untreated SKBR3
cells (Figure 6).Discussion
We have constructed the Gluc-LiDps-ZnPP conjugate for
the first time and this has the ability to generate ROS via
BRET. The nanoconstruct retains the structure of the native
protein as determined by Circular Dichroism (Figure SI3) and
self-assembles into a cage with external diameter ~ 9 nm
and the expected molecular weight.22 Our studies show that
the fusion of Gluc and LiDps significantly enhances the
bioluminescence lifetime of Gluc. We attribute the prolonged
luminescence of Gluc-LiDps to a decrease in the coelenter-
azine turnover rate caused by the steric hindrance of the active
site of Gluc by LiDps rather than a reduction in the amount of
correctly folded protein. This explanation is also supported
by further studies demonstrating that the addition of SDS to
the reaction mixture, which causes protein disassembly,37,38
reverses the observed change of bioluminescence lifetime.
This may explain why the fusion of Gluc to LiDps alters the
kinetics of the enzyme from ‘flash’, where substrate turnover is
very fast and the photoluminescent period is very short39 to
more ‘glow’ like, where substrate turnover is slower and lasts
up to 30 min. Thus incorporation of Gluc into the Gluc-LiDps-
ZnPP nanoconstruct offers a benefit of prolonged lumines-
cence lifetime for BRET.
We have studied the effect of the composition of the
nanoconstruct on BRET pair efficiency, compound stability and
solubility. The optimal ratio of ~7 ZnPPmolecules per subunit was
found to allow the efficient formation of the protein cage and
generate a stable soluble product. As expected from aBRETpair,13
following conjugation of ZnPP, the bioluminescence of Gluc at
480 nm15 was significantly quenched (N 10-times) compared to
that of a mixture of Gluc-LiDps and unconjugated ZnPP at the
same concentrations, demonstrating that the BRET process is only
efficient in the conjugates, as was previously reported for various
BRET systems.40
An in vitro assessment of the potential of Gluc-LiDps-ZnPP
as PDT agent was performed in two breast cancer cell lines
(MDA-MB-231 and SKBR3) and in non-tumorigenic MRC5
fibroblast cell line. The cell viability studies confirmed our
Figure 6. (A) The photograph of a wound healing assay performed on SKBR3 cells. The cell migration images tracked immediately after treatment t = 0 and
every 8 h thereafter. (B) The relative change of gap distance with time for SKBR3 cells as a measure of cell migration. Mean values are shown ± SD of three
independent experiments.
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induced noticeable effects on cell viability and did not induce
any change of ROS levels. Only Gluc-LiDps-ZnPP in the
presence of coelenterazine led to growth inhibitions, confirning
efficient energy transfer from Gluc to ZnPP. Activation of ZnPP
results in ROS-generation20 leading to cell death. Also, elevated
ROS levels were confirmed by the use of a ROS assay for Gluc-
LiDps-ZnPP in the presence of coelenterazine. We conclude,
that the ROS generation in our nano-construct is due to presence
of ZnPP, which is known for its ability to photo-generate singlet
oxygen species.19 The mechanism of ROS generation in our
nanoconstruct remains the same as that of ZnPP, which is
ascribed to alterations of cell cycle regulation41: upon absorptionof photon, the first excited triplet state is formed with long
lifetime, the energy is transferred to oxygen forming reactive
singlet molecular oxygen.42 We also note that the activity of our
nanoplatform is comparable to that of ZnPP, indicating that the
purification step efficiently removed contamination, and even if
negligible amounts of contaminants (e.g. lipopolysaccharides)
are present, they do not alter PDT activity. The key advantage of
our approach is the activation of ROS generation through BRET,
i.e. without the need for external source of energy, which is
beneficial for deep tissue applications.
Interestingly, we find a 2-fold difference in the uptake of the
Gluc-LiDps-ZnPP nanoconstruct by SKBR3 cells compared to
MDA-MB-231 cells, and negligible levels of uptake by MRC5
9A.W. Al-Ani et al / Nanomedicine: Nanotechnology, Biology, and Medicine 20 (2019) 102005cells. We note, that ZnPP alone non-selectively penetrates all
studied cells in significantly greater quantities compared to
Gluc-LiDps-ZnPP. The observed differences in the uptake are
likely due to the presence of specific receptors.43 Dominating
internalization pathways for ferritin-and Dps-family proteins is
through endocytosis, where presence of specific receptors
and particular selectivity for TfR1 overexpressing cell lines is
widely acknowledged.44 Non-selective internalization of these
proteins is observed via endocytosis through clathrin-coated pits.
Further detailed studies are required to confirm the mechanism of
internalization. Receptor mediated uptake of fusion protein
potentially could offer some selectivity for the delivery and
distribution of ZnPP towards cancer cells. In agreement with the
observed 2-fold greater uptake is the accompanying 2-fold higher
level of ROS in Gluc-LiDps-ZnPP treated SKBR3 cells compared
to MDA-MB-231 cells. These results confirm our PDT agent
effectively generates ROS and the elevated ROS levels in SKBR3
cells sensitizes these cells to the treatment of Gluc-LiDps-ZnPP
with coelenterazine.
Cell migration is an indicator of changes in the cell
physiological and pathological processes.45 We note, that
following exposure to the Gluc-LiDps-ZnPP nanoconstruct affects
the ability of cells to migrate, which is of potential benefit for
applications in PDT. Further in vivo studies are needed to assess
the blood clearance time, enhanced permeability and retention
(EPR) effect, and the possible immune response of the conjugate
which if significant, could be addressed by conjugation of Gluc-
LiDps-ZnPP with polyethylene glycol (PEG) to reduce any
immune system stimulation.46,47 Also, in vivo studies will clarify
any potential differences between the activity of our nanoplatform
and its biodistribution, with particular focus on its interaction with
HO-1, which is primarily found in the spleen, liver and kidneys
although its level in other cells is raised during stress.
In conclusion we have developed a PDT ‘nanoplatform’
activated via BRET with a luciferin (Gluc-LiDps-ZnPP) and
demonstrated in vitro its ROS generating ability in cancer cells.
The conjugate was found to have enhanced uptake and higher
cytotoxicity in breast cancer cells (MDA-MB-231; SKBR3)
compared to the non-tumorigenic cells examined, demonstrating
the significant potential of Gluc-LiDps-ZnPP to be used as a self-
illuminating - PDT agent for cancer therapy. This system offers
several advantages over the previously reported QD-luciferase/e6-
chlorin and luciferase-Rose Bengal BRET/PDT systems including:
fewer steps to construct the agent; a completely biodegradable agent
that maximizes BRET and hence PDT efficiency by keeping the
luciferase and photosensitizer in close proximity; the use of a
biocompatible coelentrazine that is known to have good biodistribu-
tion and low toxicity in vivo. The presence of the hollow cavity of
LiDps offers additional opportunities for encapsulation and delivery
of drugs and/or imaging agents,48 while the exterior surface of the
LiDps can be further modified with selective targeting ligands such
as antibody fragments or peptides that target receptors over-
expressed on tumors.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.nano.2019.04.008.References
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